Tuberous sclerosis complex is a genetic condition that affects the body in many different ways, causing noncancerous growths to develop in multiple organs. While there is no cure for this lifelong condition, modern medicine offers a range of treatment strategies designed to control symptoms, slow disease progression, and improve the quality of life for those affected—from newborns to adults.

How Treatment Helps Manage Tuberous Sclerosis Complex

The primary goal when treating tuberous sclerosis complex (TSC) is not to cure the condition—since currently no cure exists—but rather to focus on preventing complications and managing the wide variety of symptoms that can appear at different stages of life. Treatment aims to control seizures that frequently occur in people with TSC, to address developmental delays and behavioral challenges, to shrink or monitor tumors that can affect the brain, kidneys, and other organs, and to improve overall physical and mental well-being.^[1] Because this condition manifests differently in each person, treatment plans must be highly individualized. Some individuals with TSC may experience only mild symptoms and live largely independent lives, while others may need continuous medical support throughout their lifetime.^[4]

The severity of TSC often depends on which organs are affected and how large the tumors grow. For instance, cortical tubers (abnormal clusters of cells in the brain) can trigger seizures, while kidney tumors might cause pain or internal bleeding if they grow too large.^[1] This variability means that doctors must regularly monitor patients through imaging studies like MRI scans, ultrasounds, and CT scans to track tumor growth and adjust treatments accordingly.^[10] Early diagnosis and intervention are considered key to optimizing long-term outcomes and preventing severe complications, which is why comprehensive, lifelong surveillance is essential for people with TSC.^[4]

Treatment strategies for TSC are guided by established clinical guidelines from medical societies around the world. These recommendations emphasize the importance of a multidisciplinary approach, meaning that specialists from different fields—such as neurology, nephrology (kidney specialists), dermatology (skin specialists), cardiology (heart specialists), and psychiatry—work together to address the many facets of this condition.^[21] This team-based care ensures that all symptoms and potential complications are managed in a coordinated way. In addition to standard treatments that have been used for years, there is ongoing research into new and innovative therapies, including drugs currently being tested in clinical trials. These experimental treatments offer hope for better symptom control and improved quality of life in the future.^[13]

Standard Approaches to Managing Tuberous Sclerosis Complex

The cornerstone of standard treatment for TSC involves managing epilepsy, which affects approximately 85 percent of individuals with this condition. Seizures can begin in infancy—often presenting as infantile spasms, which involve brief, repetitive muscle contractions in the head, trunk, arms, and legs—and may persist or change in type as the person grows older.^[5] Controlling seizures is critical because uncontrolled epilepsy can worsen cognitive and behavioral problems, so antiepileptic drugs (AEDs) are typically prescribed as the first line of defense.^[12]

One of the most commonly used medications for infantile spasms in children with TSC is vigabatrin. This drug is considered the first choice for this specific type of seizure because studies have shown it can reduce both the frequency and severity of spasms. When given early, vigabatrin may even help prevent the development of more severe forms of epilepsy later in life, although its benefits for addressing cognitive and behavioral difficulties remain less clear.^[14] Other antiepileptic medications that may be used include topiramate, lamotrigine, valproate, and in some cases, hormonal treatments such as adrenocorticotropic hormone (ACTH) or steroids.^[12] For older children and adults with TSC who experience different types of seizures, the choice of medication depends on the specific seizure pattern and the individual’s overall health.^[12]

In 2020, a medication called cannabidiol (a highly purified form of a compound found in cannabis) was approved in the United States for treating seizures in children aged one year and older who have TSC. This medication represents a newer option for families seeking alternatives to traditional antiepileptic drugs.^[12] Unfortunately, many people with TSC have seizures that are difficult to control with medication alone—a condition known as refractory epilepsy. For these individuals, doctors may consider surgical options, such as removing the specific area of the brain causing the seizures, or using devices like a vagus nerve stimulator, which sends electrical impulses to the brain to help reduce seizure frequency.^[16]

Beyond epilepsy, standard treatment also addresses the many other organ systems affected by TSC. For example, tumors in the brain called subependymal giant cell astrocytomas (SEGAs) can grow large enough to block the flow of cerebrospinal fluid, leading to a dangerous buildup of pressure inside the skull. In the past, surgery was the main option for removing these tumors, but today, targeted medications (discussed below) can often shrink them without the need for an operation.^[16] Kidney problems, such as angiomyolipomas (benign tumors made of fatty tissue and muscle cells) and cysts, are also common in TSC. While these kidney lesions may not cause symptoms initially, they can grow large enough to cause pain, bleeding, or even kidney failure. Regular monitoring with ultrasound or other imaging is essential to catch problems early.^[1]

Skin abnormalities are among the most visible signs of TSC and can be treated with various methods. For instance, facial angiofibromas—reddish bumps that often appear on the face and resemble acne—can be removed or reduced using laser therapy or other dermatological procedures. In 2022, a topical form of a medication called sirolimus received approval in the United States for treating facial angiofibromas in patients six years and older.^[12] Other skin changes, such as white patches or thickened areas, may not require treatment unless they cause discomfort or cosmetic concerns.^[2]

Heart tumors, known as cardiac rhabdomyomas, are often detected before birth during routine prenatal ultrasounds and are most common in newborns and infants. These growths usually shrink on their own over time and rarely require treatment. However, if they interfere with blood flow or cause irregular heart rhythms, doctors may need to monitor the child closely or, in rare cases, perform surgery.^[8] Similarly, lung involvement—particularly a condition called lymphangioleiomyomatosis (LAM)—mostly affects women of childbearing age or older. LAM can cause shortness of breath and other breathing difficulties, and while some people remain symptom-free, others may experience progressive lung damage requiring medication or even lung transplantation in severe cases.^[1]

The duration of treatment varies depending on the specific symptoms being addressed. Antiepileptic drugs, for example, may be needed for years or even for a lifetime if seizures persist. Regular follow-up appointments are crucial to monitor the effectiveness of medications and to adjust doses as needed. Side effects are an important consideration with all TSC treatments. Antiepileptic drugs can cause drowsiness, dizziness, mood changes, or other unwanted effects, and families should report these to their healthcare team so that adjustments can be made.^[12]

Innovative Therapies Being Tested in Clinical Trials

One of the most promising areas of research in TSC treatment involves drugs that target the underlying biological problem causing the condition. Scientists have discovered that TSC results from mutations in either the TSC1 or TSC2 gene, which normally produce proteins called hamartin and tuberin. These proteins work together to regulate a key molecule in cells known as mTOR (mammalian target of rapamycin). When mTOR is not properly controlled due to faulty TSC1 or TSC2 genes, cells grow and divide too rapidly, leading to the formation of tumors throughout the body.^[9]

Understanding this mechanism has led to the development of mTOR inhibitors, a class of medications designed to block the overactive mTOR pathway and thereby slow down or shrink tumor growth. One such drug, everolimus, has been extensively studied in clinical trials and is now approved in multiple countries, including the United States and across Europe, for several TSC-related conditions.^[12] Everolimus is approved for adults with kidney tumors (angiomyolipomas) who do not need immediate surgery, and it is also approved for adults and children aged one year and older with brain tumors (SEGAs) that cannot be completely removed surgically. Additionally, everolimus has been approved for treating seizures in adults and children as young as two years old who have TSC.^[12]

Clinical trials testing everolimus have shown that it can significantly reduce the size of both brain and kidney tumors. In studies focusing on seizures, patients taking everolimus experienced notable reductions in seizure frequency compared to those taking a placebo. These improvements were sustained even after two years of continuous treatment, suggesting that the drug provides long-lasting benefits.^[12] The mechanism behind everolimus involves directly inhibiting the mTOR protein, which in turn slows down the abnormal cell growth that characterizes TSC. By addressing the root cause at a molecular level, mTOR inhibitors represent a form of precision medicine—treatment tailored to the specific genetic and biological features of a disease.^[14]

Another mTOR inhibitor, sirolimus, has also been studied for TSC. While it is primarily approved in the United States for treating a lung condition called lymphangioleiomyomatosis (which can occur in people with TSC), sirolimus is sometimes used off-label for other TSC-related symptoms. The topical version of sirolimus has received approval for treating facial angiofibromas, as mentioned earlier.^[12] Both everolimus and sirolimus share a similar mechanism of action, and ongoing research continues to explore the best ways to use these drugs, including whether they can be used preventively to stop tumors from forming in the first place.^[14]

The concept of preventative treatment is an exciting frontier in TSC research. Some clinical trials are investigating whether starting mTOR inhibitors very early in life—before tumors have had a chance to grow or before seizures begin—might improve long-term outcomes, including reducing the severity of cognitive and behavioral impairments. For instance, vigabatrin has already shown promise when given preventively to reduce the risk and severity of epilepsy, and researchers are now asking whether everolimus or other drugs could offer similar preventive benefits.^[14]

Another innovative therapy being explored for TSC-related seizures is the ketogenic diet, a high-fat, low-carbohydrate eating plan that has been used for decades to treat epilepsy. Emerging evidence suggests that the ketogenic diet may influence the mTOR pathway, potentially offering an additional way to control both seizures and tumor growth in TSC. While not a drug, the ketogenic diet is being studied in clinical trials to better understand its effectiveness and safety as part of a comprehensive treatment plan.^[14]

Clinical trials for TSC are being conducted around the world, including in the United States, Europe, and other regions. These studies typically progress through three phases. Phase I trials focus on safety, testing whether a new drug or treatment is safe for humans and determining the appropriate dose. Phase II trials assess whether the treatment is effective, meaning whether it actually improves symptoms or shrinks tumors. Phase III trials compare the new treatment to the current standard of care to determine which approach works best.^[13] Patients who participate in clinical trials play a crucial role in advancing medical knowledge and may gain early access to cutting-edge therapies that are not yet widely available.

Eligibility for clinical trials varies depending on the specific study, but generally, researchers look for participants who meet certain criteria, such as age, disease severity, and previous treatments. Families interested in participating should discuss options with their healthcare team, who can help identify appropriate trials and explain the potential risks and benefits. Many clinical trials for TSC are listed on registries such as ClinicalTrials.gov, where detailed information about ongoing studies can be found.^[13]

Most common treatment methods

• Antiepileptic medications
  • Vigabatrin is the first-choice drug for infantile spasms in children with TSC and has been shown to reduce seizure frequency and severity.^[14]
  • Topiramate, lamotrigine, valproate, and ACTH or steroids are also used depending on seizure type and patient characteristics.^[12]
  • Cannabidiol was approved in 2020 in the United States for TSC-associated seizures in children aged one year and older.^[12]
  • Medication choice depends on the specific seizure pattern, the patient’s age, and potential side effects.^[12]
• mTOR inhibitors (targeted therapy)
  • Everolimus is approved for treating brain tumors (SEGAs), kidney tumors (angiomyolipomas), and seizures in patients with TSC.^[12]
  • Everolimus works by blocking the mTOR protein, which controls cell growth and division, thereby slowing or shrinking tumor growth.^[14]
  • Clinical trials have demonstrated significant reductions in tumor size and seizure frequency, with benefits sustained over two years of treatment.^[12]
  • Sirolimus is another mTOR inhibitor approved for lymphangioleiomyomatosis and available in topical form for facial angiofibromas.^[12]
• Surgical interventions
  • Surgery may be needed to remove brain tumors (SEGAs) that block cerebrospinal fluid flow or cannot be controlled with medication.^[16]
  • Kidney tumors (angiomyolipomas) may require surgical removal if they grow large enough to cause bleeding or kidney failure.^[1]
  • Epilepsy surgery can be considered for patients with refractory seizures that do not respond to medication.^[16]
  • Skin growths, such as facial angiofibromas, can be treated with laser therapy or surgical removal for cosmetic or functional reasons.^[2]
• Neuromodulation devices
  • Vagus nerve stimulation involves implanting a device that sends electrical impulses to the brain to reduce seizure frequency.^[16]
  • This minimally invasive approach is an alternative for patients whose seizures are difficult to control with medication alone.^[16]
• Supportive therapies
  • Educational and occupational therapy can help maximize the ability to perform everyday tasks and improve quality of life.^[16]
  • Behavioral interventions and psychiatric care are important for managing TSC-associated neuropsychiatric disorders (TAND), including autism, anxiety, and ADHD.^[1]
  • The ketogenic diet is being studied as a potential treatment for seizures and may also influence the mTOR pathway.^[14]
• Regular monitoring and surveillance
  • MRI scans, ultrasounds, CT scans, and other imaging studies are used throughout life to monitor tumor growth and detect complications early.^[10]
  • Eye exams, electrocardiograms, echocardiograms, and kidney function tests are part of routine surveillance.^[10]
  • Regular follow-up appointments with a multidisciplinary team of specialists ensure comprehensive care.^[21]